Vamil Divan
Stock Analyst at Guggenheim
(4.69)
# 203
Out of 4,761 analysts
216
Total ratings
65.73%
Success rate
18.39%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Buy | $122 → $115 | $89.50 | +28.49% | 13 | Feb 12, 2025 | |
| PFE Pfizer | Reiterates: Buy | $33 | $26.30 | +25.48% | 20 | Feb 10, 2025 | |
| INSM Insmed | Maintains: Buy | $95 → $101 | $81.06 | +24.60% | 5 | Feb 7, 2025 | |
| ABBV AbbVie | Maintains: Buy | $212 → $214 | $202.08 | +5.90% | 23 | Feb 3, 2025 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $162 → $166 | $162.30 | +2.28% | 12 | Feb 3, 2025 | |
| KROS Keros Therapeutics | Reiterates: Neutral | n/a | $11.02 | - | 5 | Jan 17, 2025 | |
| ABSI Absci | Reiterates: Buy | $10 | $4.96 | +101.61% | 2 | Dec 3, 2024 | |
| VERA Vera Therapeutics | Maintains: Buy | $56 → $64 | $28.58 | +123.93% | 4 | Oct 28, 2024 | |
| TVTX Travere Therapeutics | Maintains: Buy | $23 → $41 | $21.98 | +86.53% | 7 | Oct 9, 2024 | |
| PROK ProKidney | Initiates: Buy | $6 | $1.50 | +300.00% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.37 | - | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $77 | $57.94 | +32.90% | 8 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $20 | $7.31 | +173.60% | 9 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $0.30 | +8,713.56% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $1.07 | +741.12% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.40 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $19.95 | -4.76% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $120.69 | -18.80% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $35.32 | -3.74% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.06 | +385.44% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $137.75 | -64.43% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $873.68 | -59.25% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $3.75 | +60.00% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $36.91 | +317.23% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $13.99 | +7.22% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $26.74 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $16.74 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $4.19 | +258.00% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $55.83 | +9.26% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $1.82 | +5,559.34% | 3 | Jan 17, 2018 |
Merck & Co.
Feb 12, 2025
Maintains: Buy
Price Target: $122 → $115
Current: $89.50
Upside: +28.49%
Pfizer
Feb 10, 2025
Reiterates: Buy
Price Target: $33
Current: $26.30
Upside: +25.48%
Insmed
Feb 7, 2025
Maintains: Buy
Price Target: $95 → $101
Current: $81.06
Upside: +24.60%
AbbVie
Feb 3, 2025
Maintains: Buy
Price Target: $212 → $214
Current: $202.08
Upside: +5.90%
Johnson & Johnson
Feb 3, 2025
Maintains: Neutral
Price Target: $162 → $166
Current: $162.30
Upside: +2.28%
Keros Therapeutics
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $11.02
Upside: -
Absci
Dec 3, 2024
Reiterates: Buy
Price Target: $10
Current: $4.96
Upside: +101.61%
Vera Therapeutics
Oct 28, 2024
Maintains: Buy
Price Target: $56 → $64
Current: $28.58
Upside: +123.93%
Travere Therapeutics
Oct 9, 2024
Maintains: Buy
Price Target: $23 → $41
Current: $21.98
Upside: +86.53%
ProKidney
Sep 10, 2024
Initiates: Buy
Price Target: $6
Current: $1.50
Upside: +300.00%
Jun 18, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.37
Upside: -
Apr 23, 2024
Reiterates: Buy
Price Target: $77
Current: $57.94
Upside: +32.90%
Sep 7, 2023
Maintains: Neutral
Price Target: $19 → $20
Current: $7.31
Upside: +173.60%
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $0.30
Upside: +8,713.56%
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $1.07
Upside: +741.12%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.40
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $19.95
Upside: -4.76%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $120.69
Upside: -18.80%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $35.32
Upside: -3.74%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $2.06
Upside: +385.44%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $137.75
Upside: -64.43%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $873.68
Upside: -59.25%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $3.75
Upside: +60.00%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $36.91
Upside: +317.23%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $13.99
Upside: +7.22%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $26.74
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $16.74
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $4.19
Upside: +258.00%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $55.83
Upside: +9.26%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $1.82
Upside: +5,559.34%